Hyperimmune immunoglobulin for people with COVID-19
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: Using a living systematic review approach, to assess whether hyperimmune immunoglobulin therapy is effective and safe in the treatment of people with COVID‐19; and to maintain the currency of the evidence.
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Cochrane Collaboration
2021
|
| _version_ | 1797108968642838528 |
|---|---|
| author | Kimber, C Valk, SJ Chai, KL Piechotta, V Iannizzi, C Monsef, I Wood, EM Lamikanra, AA Roberts, DJ McQuilten, Z So-Osman, C Estcourt, LJ Skoetz, N |
| author_facet | Kimber, C Valk, SJ Chai, KL Piechotta, V Iannizzi, C Monsef, I Wood, EM Lamikanra, AA Roberts, DJ McQuilten, Z So-Osman, C Estcourt, LJ Skoetz, N |
| author_sort | Kimber, C |
| collection | OXFORD |
| description | This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
Using a living systematic review approach, to assess whether hyperimmune immunoglobulin therapy is effective and safe in the treatment of people with COVID‐19; and to maintain the currency of the evidence.
|
| first_indexed | 2024-03-07T07:35:24Z |
| format | Journal article |
| id | oxford-uuid:bff4c6ec-1ef0-432b-ac59-74c25fcfda56 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:35:24Z |
| publishDate | 2021 |
| publisher | Cochrane Collaboration |
| record_format | dspace |
| spelling | oxford-uuid:bff4c6ec-1ef0-432b-ac59-74c25fcfda562023-02-27T13:39:59ZHyperimmune immunoglobulin for people with COVID-19Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bff4c6ec-1ef0-432b-ac59-74c25fcfda56EnglishSymplectic Elements Cochrane Collaboration2021Kimber, CValk, SJChai, KLPiechotta, VIannizzi, CMonsef, IWood, EMLamikanra, AARoberts, DJMcQuilten, ZSo-Osman, CEstcourt, LJSkoetz, NThis is a protocol for a Cochrane Review (intervention). The objectives are as follows: Using a living systematic review approach, to assess whether hyperimmune immunoglobulin therapy is effective and safe in the treatment of people with COVID‐19; and to maintain the currency of the evidence. |
| spellingShingle | Kimber, C Valk, SJ Chai, KL Piechotta, V Iannizzi, C Monsef, I Wood, EM Lamikanra, AA Roberts, DJ McQuilten, Z So-Osman, C Estcourt, LJ Skoetz, N Hyperimmune immunoglobulin for people with COVID-19 |
| title | Hyperimmune immunoglobulin for people with COVID-19 |
| title_full | Hyperimmune immunoglobulin for people with COVID-19 |
| title_fullStr | Hyperimmune immunoglobulin for people with COVID-19 |
| title_full_unstemmed | Hyperimmune immunoglobulin for people with COVID-19 |
| title_short | Hyperimmune immunoglobulin for people with COVID-19 |
| title_sort | hyperimmune immunoglobulin for people with covid 19 |
| work_keys_str_mv | AT kimberc hyperimmuneimmunoglobulinforpeoplewithcovid19 AT valksj hyperimmuneimmunoglobulinforpeoplewithcovid19 AT chaikl hyperimmuneimmunoglobulinforpeoplewithcovid19 AT piechottav hyperimmuneimmunoglobulinforpeoplewithcovid19 AT iannizzic hyperimmuneimmunoglobulinforpeoplewithcovid19 AT monsefi hyperimmuneimmunoglobulinforpeoplewithcovid19 AT woodem hyperimmuneimmunoglobulinforpeoplewithcovid19 AT lamikanraaa hyperimmuneimmunoglobulinforpeoplewithcovid19 AT robertsdj hyperimmuneimmunoglobulinforpeoplewithcovid19 AT mcquiltenz hyperimmuneimmunoglobulinforpeoplewithcovid19 AT soosmanc hyperimmuneimmunoglobulinforpeoplewithcovid19 AT estcourtlj hyperimmuneimmunoglobulinforpeoplewithcovid19 AT skoetzn hyperimmuneimmunoglobulinforpeoplewithcovid19 |